Global Endowment Management LP increased its holdings in Allergan PLC. (NYSE:AGN) by 4.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,640 shares of the company’s stock after purchasing an additional 600 shares during the quarter. Global Endowment Management LP’s holdings in Allergan PLC. were worth $3,316,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of AGN. Veritas Asset Management LLP bought a new stake in shares of Allergan PLC. in the first quarter worth $761,339,000. Iridian Asset Management LLC CT grew its stake in shares of Allergan PLC. by 141.3% in the first quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock worth $306,733,000 after purchasing an additional 751,848 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Allergan PLC. in the first quarter worth $124,255,000. Vanguard Group Inc. grew its stake in shares of Allergan PLC. by 2.2% in the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock worth $5,551,128,000 after purchasing an additional 482,220 shares during the last quarter. Finally, Blue Ridge Capital L.L.C. grew its stake in shares of Allergan PLC. by 24.1% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock worth $456,313,000 after purchasing an additional 370,400 shares during the last quarter. 82.03% of the stock is currently owned by institutional investors.

Shares of Allergan PLC. (NYSE:AGN) opened at 206.75 on Friday. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The firm’s 50-day moving average is $218.50 and its 200-day moving average is $233.15. The company has a market cap of $69.12 billion, a PE ratio of 6.30 and a beta of 1.15.

Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the prior year, the business earned $3.35 earnings per share. Allergan PLC.’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, equities research analysts predict that Allergan PLC. will post $16.21 earnings per share for the current year.

Allergan PLC. declared that its Board of Directors has authorized a share buyback program on Monday, September 25th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to buy up to 2.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

The business also recently announced a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were given a dividend of $0.70 per share. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.35%. Allergan PLC.’s dividend payout ratio is 9.95%.

Several analysts recently weighed in on the stock. Piper Jaffray Companies set a $227.00 price objective on shares of Allergan PLC. and gave the stock a “hold” rating in a research note on Friday. Wells Fargo & Company reissued a “buy” rating on shares of Allergan PLC. in a research note on Monday, October 2nd. Barclays PLC reissued an “equal weight” rating on shares of Allergan PLC. in a research note on Monday, October 2nd. UBS AG reissued a “buy” rating and issued a $275.00 price objective on shares of Allergan PLC. in a research note on Tuesday, September 26th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $266.00 price objective (down previously from $286.00) on shares of Allergan PLC. in a research note on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $271.64.

ILLEGAL ACTIVITY WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/global-endowment-management-lp-has-3-32-million-position-in-allergan-plc-agn/1617434.html.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.